logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Inovio: Exciting News Published in The Lancet

Inovio Phase 1 Data of INO-4800 for COVID-19 Peer-reviewed Phase 1 data shows Inovio COVID-19 DNA Vaccine Candidate, INO-4800, to be immunogenic in 100% of subjects, inducing neutralizing antibody and/or T cell responses. INO-4800 demonstrates favorable safety and tolerability. No...

Read More

December 24, 2020

0

For Those Still Asking Why the CRiSPR Gene Editing Stocks are Soaring

Intellia Therapeutics and CRISPR/Cas9 Technology Intellia Therapeutics ( NTLA ) is a genome editing company, focused on the development of potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by both...

Read More

January 7, 2021

0

Underlining Exelixis Bright Future

Exelixis Bright Future Exelixis Fourth Quarter and Full Year 2020 Financial Results   Exelixis ( EXEL ) announced its preliminary unaudited financial results for the Fourth Quarter and Full Year 2020. It also provided financial guidance for the full year...

Read More

January 11, 2021

0

La Jolla Pharmaceutical Company Announced an Exclusive Licensing Agreement for GIAPREZA and XERAVA in Europe

La Jolla Pharmaceutical Company Announced an Exclusive Licensing Agreement for GIAPREZA and XERAVA La Jolla Pharmaceutical Company ( LJPC ) announced today in a press release that it and certain of its wholly-owned subsidiaries, La Jolla collectively, have entered into...

Read More

January 12, 2021

0

Exelixis' Good News. Prohost Comprehensive Essay with Informative Real Stories About Biotech Stocks

Coming Soon at Prohost Biotech We have stories to tell about our picked stocks which we believe could deepen the Prohost Biotech readers’ understanding of our strategy regarding the evaluation of the biotech companies. Our strategy has made it possible...

Read More

January 7, 2020

0

Cassava Sciences Guidance for Simufilam. See Also: Its First Quarter 2021 Financial Results

Cassava Sciences Guidance and Financial Results Cassava Sciences ( SAVA ) announced financial results for the first quarter ended March 31, 2021 as well as its guidance regarding the release of new clinical data with simufilam, the Company’s lead drug...

Read More

April 21, 2021

0

Sutro Biopharma Dosed the First Patient in the Dose-Expansion Cohort of the Phase 1 STRO-002 Study

Sutro Biopharma Therapeutic Discovery and Technology Sutro Biopharma ( STRO ) uses precise protein engineering and rational design for therapeutic discovery. The firm’s proprietary integrated cell-free protein synthesis platform known as XpressCF® and site-specific conjugation platform XpressCF+™ led to the...

Read More

January 21, 2021

0

Why the Recent Data from the Trial of Moderna's mRNA Vaccine is Important and Significant

Moderna's mRNA Vaccine Today could be one of the important early days as Moderna ( MRNA ) succeeded in cementing proof of concept for the validity of its messenger RNA ( mRNA ) as a vaccine. Moderna announced yesterday positive...

Read More

January 10, 2020

0

Bristol-Myers Squibb: CHMP of the EMA Recommended Additional Approval of Onureg® as Maintenance Therapy for AML

European Authorities Recommended Additional Approval of Bristol-Myers Squibb Product Onureg® for AML Bristol-Myers Squibb ( BMY ) : The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) recommended approval of...

Read More

April 23, 2021

0

Gilead and Eisai Submitted an Application to Japan's PMDA for Approval of Filgotinib for UC

Gilead Sciences and Eisai Pharmaceutical Co Submitted an Application to Japan's PMDA for Filgotinib Galapagos NV ( GLPG )  announced that  Gilead Sciences ( GILD )  and Eisai Pharmaceutical Co ( ESALY )  submitted an application to Japan’s Pharmaceuticals and Medical...

Read More

April 23, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 109
  • 110
  • 111
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy